<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335526</url>
  </required_header>
  <id_info>
    <org_study_id>MMP2</org_study_id>
    <nct_id>NCT04335526</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Assess the Effect of Change of Bile Acid on the PD and Safety of Metformin and Microbiome Profiles</brief_title>
  <official_title>A Clinical Study for Assessing the Effect of Change of Bile Acid Pool on the Pharmacodynamics and Safety of Metformin and Intestinal Microbiome Profiles in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is intended to evaluate the effect of change of bile acid pool with&#xD;
      cholestyramine on the pharmacodynamics and safety of metformin and intestinal microbiome&#xD;
      profiles in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Actual">October 21, 2020</completion_date>
  <primary_completion_date type="Actual">July 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the maximum blood glucose concentration (Gmax)</measure>
    <time_frame>Day 1/2/8/9 (pre-dose (75 g glucose), 0.25, 0.5, 0.75, 1, 1.5. 2 hours)</time_frame>
    <description>Compare the maximum blood glucose concentration (Gmax) between meformin alone and meformin with cholestyramine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the maximum blood glucose concentration (Gmax)</measure>
    <time_frame>Day 1/2/8/9 (pre-dose (75 g glucose), 0.25, 0.5, 0.75, 1, 1.5. 2 hours)</time_frame>
    <description>Compare the area under the blood glucose concentration versus time curve (AUC) between meformin alone and meformin with cholestyramine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the gut microbiome species change</measure>
    <time_frame>Day 1/2/8/9</time_frame>
    <description>Compare how the gut microbiome species change between meformin alone and meformin with cholestyramine</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Human Microbiome</condition>
  <arm_group>
    <arm_group_label>Metformin alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin with cholestyramine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholestyramine Resin</intervention_name>
    <description>Change bile acid pool by cholestyramine treatment</description>
    <arm_group_label>Metformin with cholestyramine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 19 to 50, healthy male subjects(at screening)&#xD;
&#xD;
          -  Body weight between 50.0 kg - 100.0 kg, BMI between 18.0 - 28.0 kg/m2&#xD;
&#xD;
          -  Subject who totally understand the progress of this clinical trials, make decision by&#xD;
             his free will, and signed a consent form to follow the progress&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject who has a past or present history of any diseases following below.(liver,&#xD;
             kidney, neurology, immunology, pulmonary, endocrine, hematology, oncology, cardiology,&#xD;
             mental disorder)&#xD;
&#xD;
          -  Subject who had GI tract disease(Crohn's disease, ulcer, acute or chronic&#xD;
             pancreatitis) or surgery (appendectomy, hernioplasty are excluded)&#xD;
&#xD;
          -  Serum AST(SGOT), ALT(SGPT)&gt;2 times upper limit of normal range MDRD eGFR&#xD;
             &lt;80mL/min/1.73m2&#xD;
&#xD;
          -  Subject who had drug (Aspirin, antibiotics) hypersensitivity reaction&#xD;
&#xD;
          -  Subject who already participated in other trials in 3 months&#xD;
&#xD;
          -  Subject who had whole blood donation in 2 months, or component blood donation in 1&#xD;
             month or transfusion in 1 month currently&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chung Jae Yong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jae Yong Chung, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestyramine Resin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

